Drug repositioning framework by incorporating functional information.

As a shortcut for drug development, drug repositioning draws more and more attention in pharmaceutical industry to identify new indications for marketed drugs or drugs failed in late clinical trial phase. At the same time, the abundant high-throughput data pushes the computationally repositioning drugs a hot topic in the area of systems biology. Here, the authors propose a general framework for repositioning drug by incorporating various functional information. The framework starts with the identification of differentially expressed gene sets under disease state and drug treatment. Then the disease and drug are associated by the overlap of these two gene sets via biological function. The authors provide two strategies to assess the functional overlap. In the first strategy, functional relevance are evaluated by leveraging genes' lethality information to reveal drug's potential of curing diseases. In the second strategy, biological process perturbation profiles are identified by mapping differentially expressed genes into pathways and gene ontology (GO) terms. Their associations are assessed and used to rank drugs' potential of curing diseases. The preliminary results on prostate cancer demonstrate that our new framework improves the drug repositioning efficiency and various function information could complement each other. Importantly, the new framework will enhance the biological interpretation and rationale of drug repositioning and provide insights into drug action mechanisms.

[1]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[2]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[3]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[4]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[5]  Dennis B. Troup,et al.  NCBI GEO: mining millions of expression profiles—database and tools , 2004, Nucleic Acids Res..

[6]  Asher Mullard,et al.  2011 FDA drug approvals , 2012, Nature Reviews Drug Discovery.

[7]  Xing-Ming Zhao,et al.  NARROMI: a noise and redundancy reduction technique improves accuracy of gene regulatory network inference , 2013, Bioinform..

[8]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[9]  Yajie Wang,et al.  Using Functional Signatures to Identify Repositioned Drugs for Breast, Myelogenous Leukemia and Prostate Cancer , 2012, PLoS Comput. Biol..

[10]  Tao Zeng,et al.  Reconstructing dynamic gene regulatory networks from sample-based transcriptional data , 2012, Nucleic acids research.

[11]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[12]  Kazuyuki Aihara,et al.  Identifying critical transitions and their leading biomolecular networks in complex diseases , 2012, Scientific Reports.

[13]  Zhiwei Cao,et al.  A pathway profile-based method for drug repositioning , 2012 .

[14]  Luonan Chen,et al.  Coexpression network analysis in chronic hepatitis B and C hepatic lesions reveals distinct patterns of disease progression to hepatocellular carcinoma. , 2012, Journal of molecular cell biology.

[15]  Kazuyuki Aihara,et al.  Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers , 2012, Scientific Reports.

[16]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[17]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[18]  Xing-Ming Zhao,et al.  Identifying disease genes and module biomarkers by differential interactions , 2012, J. Am. Medical Informatics Assoc..

[19]  Yidong Chen,et al.  Using gene sets to identify putative drugs for breast cancer , 2012, 2012 IEEE International Conference on Bioinformatics and Biomedicine.

[20]  Shiwen Zhao,et al.  A co-module approach for elucidating drug-disease associations and revealing their molecular basis , 2012, Bioinform..

[21]  A. Butte,et al.  AILUN: reannotating gene expression data automatically , 2007, Nature Methods.

[22]  Lin He,et al.  DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein interactome , 2011, Nucleic Acids Res..

[23]  Stephen T. C. Wong,et al.  A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. , 2012, Cancer research.

[24]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..

[25]  J. Aronson Old drugs--new uses. , 2007, British journal of clinical pharmacology.

[26]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[27]  Lisa M. Christadore,et al.  Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis , 2011, Proceedings of the National Academy of Sciences.

[28]  Hong-Yu Ou,et al.  EG: a database of essential genes , 2004, Nucleic Acids Res..

[29]  Xing-Ming Zhao,et al.  Inferring gene regulatory networks from gene expression data by path consistency algorithm based on conditional mutual information , 2012, Bioinform..

[30]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[31]  A. H. Lipkus A proof of the triangle inequality for the Tanimoto distance , 1999 .

[32]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[33]  Luonan Chen,et al.  Network-based drug repositioning. , 2013, Molecular bioSystems.

[34]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[35]  E. Schadt,et al.  Integrative genomics and drug development. , 2009, Pharmacogenomics.

[36]  Bart De Moor,et al.  BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis , 2005, Bioinform..

[37]  Yan Zhang,et al.  Research and applications: An integrated approach to identify causal network modules of complex diseases with application to colorectal cancer , 2013, J. Am. Medical Informatics Assoc..